Company Analysis

Edesa Biotech, Inc. (EDSA)

Nasdaq: EDSA · Pharmaceutical Preparations · filing with the SEC since 2012
Grade4.5
◀ Past 5.1● Present 5.5▶ Future 3.3
5 est.

Who runs Edesa Biotech, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Nijhawan Pardeep
Chief Executive Officer. First filing Jun 2019, latest Nov 5, 2026, 18 filings in all.
Officers reporting now
3
of 9 people with a filing in the last fifteen months
Directors reporting now
6
25 people on the record since 2014
Officerssales are open-market, Nov 5, 2025 to Nov 5, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Nijhawan PardeepChief Executive OfficerJun 2019Nov 5, 2026none
Brooks Michael JPresidentJun 2019May 29, 2026none
Weiler Peter J.Chief Financial OfficerMay 2025May 29, 2026none
Directorssales are open-market, Nov 5, 2025 to Nov 5, 2026
NameRoleFirst filingLatest filingSales, 12 months
Chypyha JoandirectorMay 2023May 29, 2026none
Liu Da DaviddirectorFeb 2025May 29, 2026none
Macdonald Sean ArthurdirectorJun 2019May 29, 2026none
Marshall PatrickdirectorMay 2023May 29, 2026none
Olson Charles VdirectorDec 2016May 29, 2026none
Sistilli CarlodirectorJun 2019May 29, 2026none
Earlier names on the record16, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton EDSA · research, not advice